|Page (1) of 1 - 03/06/18||email article||print page|
Consumer Track Agenda Announced for 4th Annual Translational Microbiome Conference(March 06, 2018)
MINNEAPOLIS (PRWEB) March 06, 2018
Arrowhead Publishers released a parallel consumer track agenda for the 4th Annual Translational Microbiome Conference, April 18-20 in Boston. The conference is designed to bring together scientists at the forefront of microbiome research with pioneering business leaders at companies innovating microbiome-based medical solutions. The consumer track focuses on issues and learnings around direct-to-consumer product and service development, with an eye toward helping companies successfully (and efficiently) navigate from research and product innovation through regulation, commercialization and marketing.
“Microbiome research is delivering medical advancements across oncology, dermatology, inflammatory disorders, mental health and many related fields," said John Waslif, Managing Director of Arrowhead Publishers. “The consumer track at our 4th Annual Translational Microbiome Conference provides a forum for companies to share best practices and process solutions. People want to take control of their health with access to the same science that's making headlines in leading hospitals and medical labs, and we want to help speed the path to commercialization."
As recent discoveries illustrate the many essential roles the human microbiome plays within the human ecosystem, scientists are discovering specific variables within the microbiome can profoundly impact a variety of conditions and diseases. To support exploration of translational consumer applications, consumer track presentations and discussion topics are broadly applicable, spanning multiple disease states and addressing issues common to companies in this space.
Consumer track sessions include:
Probiotic Hygiene and Care Response
Robin Temmerman, Ph.D., Chief Executive Officer, Chrisal, N.V.
Resistance of microbes to antibiotics and disinfectants is growing quickly, and allergies to chemical ingredients in cleaning and personal care products are on the rise. Rapid evolution in microbiological research has led to promising new probiotic hygiene technologies in the form of cleaning and personal care applications. For the past 15 years, Chrisal has invested to develop product solutions to widespread hygiene problems like biofilm, smell and infections. Dr. Temmerman will discuss the technology, mechanisms and benefits of probiotic hygiene and care.
Probiotic Home: The Future of Clean
John Howell, Industry Technology Specialist HHC, Novozymes
Consumers are increasingly aware of the microbiota surrounding them, and its integral role in their healthy lifestyle. They may not yet think of microbiota as a solution to what they spill on the floor. Yet, microorganisms, or probiotics, are nature's oldest and most reliable cleaning crew. They work overtime to break down organics, for a deeper and longer-lasting “probiotic clean" than conventional chemicals. While the technology has long been used industrially, this concept has just recently started to resonate with consumers for application in their home environment. Mr. Howell will share several industrial and domestic cleaning scenarios in which microorganism-containing products are currently used, and he'll predict future consumer cleaning habits and products that will selectively reinforce the microbiome of the home.
Panel Session: The Future of Probiotic Hygiene
Moderated by Joe Rubino, R&D Director for Reckitt Benckiser, panelists will include Matt Franken, Chief Executive Officer of Aunt Fannies; Robin Temmerman, Ph.D., Chief Executive Officer of Chrisal N.V. and other industry experts.
Early Life Microbiome: Connections between Nutritional Composition, Gastrointestinal Tract and the Brain
Maciej Chichlowski, Ph.D., PMP, Principal Scientist, Mead Johnson Nutrition (RB)
Optimal development of the microbiome is an emerging health benefit that's likely to grow in consumer awareness and demand over time. Intestinal microbiota plays a role in metabolic, nutritional, physiological and immunological processes in the human body, and nutrition can affect gut microbiota colonization. Our research demonstrates that functional properties of early nutrition could benefit the microbiome and health. For instance, our studies have shown that early life diet with milk fat globule membrane and prebiotics promote immune, gut, and brain development and function.
Using Live Bacteria for Topical Skin Application: Regulatory Issues
Ingmar Claes, Ph.D., Chief Scientific Officer, Yun Probiotherapy
A growing body of data supports the importance of the skin microbiome in its role as a protective barrier against external influence. Products with live beneficial bacteria, or live biotherapeutic products (LBP's), present the potential to improve symptoms of a multitude of skin disorders. Yet, safety of probiotic strains is of critical importance during the in vitro screening phase. By building up the safety documentation and quality controls in the production of products, Yun Probiotherapy was able to overcome EU regulatory issues and begin marketing their LBP line to consumers.
“Research in the microbiome presents tremendous potential to provide more effective treatments, cures, therapies and supplements," said Waslif. “As investment opportunities are growing in this area, many companies are rapidly pursuing potential translational solutions. Therefore, sharing key learnings in this space can lend greater efficiency to the development and availability of new pharmaceutical offerings."
View the full agenda for the 4th Annual Translational Microbiome Conference at http://www.microbiomeconference.com.
Sponsors and Exhibitors can showcase products and branding in an environment designed to facilitate professional networking. Learn more via http://www.microbiomeconference.com/sponsor-exhibit.
Arrowhead Publishers brings life sciences industry professionals together to help move research forward through learning, networking and professional growth. Arrowhead focuses on offering thoughtfully curated speakers, new research industry trends, case studies, emerging discoveries and the future focus of the biotech and pharmaceutical industries. Arrowhead conferences cover clinical development and cutting-edge research, regulatory issues and market dynamics, therapeutics, drug discovery and positioning, and emerging technologies for both clinicians and pharmaceutical professionals.
If you would like more information about this announcement or the 4th Annual Translational Microbiome Conference, please contact John Waslif, Managing Director at Arrowhead Publishers via email at john.waslif(at)arrowheadpublishers.com.
Read the full story at http://www.prweb.com/releases/2018/03/prweb15283426.htm.